Triptorelin pamoate
Products billed under this code include Trelstar.
Payment limit per 3.75 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Trelstar.
Payment limit per 3.75 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Trelstar | Verity Pharmaceuticals Inc. | 74676-5902-01 | 1 | $467.059 |
| Trelstar | Verity Pharmaceuticals Inc. | 74676-5904-01 | 3 | $1,401.177 |
| Trelstar | Verity Pharmaceuticals Inc. | 74676-5906-01 | 6 | $2,802.354 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $467.059 | +$0.694 | 3.75 MG | Triptorelin pamoate | v1, posted September 17, 2026 |
| 3Q26 | $466.365 | −$3.011 | 3.75 MG | Triptorelin pamoate | v1, posted September 15, 2026 |
| 2Q26 | $469.376 | +$6.181 | 3.75 MG | Triptorelin pamoate | v1, posted September 15, 2026 |
| 1Q26 | $463.195 | −$11.643 | 3.75 MG | Triptorelin pamoate | v1, posted September 15, 2026 |
| 4Q25 | $474.838 | −$17.061 | 3.75 MG | Triptorelin pamoate | v1, posted September 8, 2026 |
| 3Q25 | $491.899 | +$20.274 | 3.75 MG | Triptorelin pamoate | v1, posted March 10, 2026 |
| 2Q25 | $471.625 | −$9.669 | 3.75 MG | Triptorelin pamoate | v1, posted March 10, 2026 |
| 1Q25 | $481.294 | +$14.567 | 3.75 MG | Triptorelin pamoate | v1, posted December 19, 2025 |
| 4Q24 | $466.727 | +$8.216 | 3.75 MG | Triptorelin pamoate | v1, posted June 11, 2025 |
| 3Q24 | $458.511 | +$41.821 | 3.75 MG | Triptorelin pamoate | v1, posted June 11, 2025 |
| 2Q24 | $416.69 | +$3.105 | 3.75 MG | Triptorelin pamoate | v1, posted March 11, 2025 |
| 1Q24 | $413.585 | +$11.84 | 3.75 MG | Triptorelin pamoate | v1, posted December 19, 2024 |
| 4Q23 | $401.745 | +$19.353 | 3.75 MG | Triptorelin pamoate | v1, posted October 10, 2024 |
| 3Q23 | $382.392 | +$17.751 | 3.75 MG | Triptorelin pamoate | v1, posted June 5, 2024 |
| 2Q23 | $364.641 | −$9.908 | 3.75 MG | Triptorelin pamoate | v1, posted February 23, 2024 |
| 1Q23 | $374.549 | +$0.764 | 3.75 MG | Triptorelin pamoate | v1, posted December 6, 2023 |
| 4Q22 | $373.785 | +$10.214 | 3.75 MG | Triptorelin pamoate | v1, posted June 22, 2023 |
| 3Q22 | $363.571 | +$15.925 | 3.75 MG | Triptorelin pamoate | v1, posted June 9, 2023 |
| 2Q22 | $347.646 | +$10.641 | 3.75 MG | Triptorelin pamoate | v1, posted December 14, 2022 |
| 1Q22 | $337.005 | −$42.899 | 3.75 MG | Triptorelin pamoate | v1, posted June 8, 2022 |
| 4Q21 | $379.904 | −$48.314 | 3.75 MG | Triptorelin pamoate | v1, posted June 2, 2022 |
| 3Q21 | $428.218 | −$87.267 | 3.75 MG | Triptorelin pamoate | v1, posted June 2, 2022 |
| 2Q21 | $515.485 | +$11.679 | 3.75 MG | Triptorelin pamoate | v1, posted March 1, 2022 |
| 1Q21 | $503.806 | – | 3.75 MG | Triptorelin pamoate | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.